Filter
166
Text search:
dolutegravir
Featured
Recommendations
17
New Publications
38
Language
Document type
No document type
81
Guidelines
36
Studies & Reports
33
Manuals
6
Strategic & Response Plan
4
Fact sheets
3
Infographics
2
Situation Updates
1
Countries / Regions
South Africa
7
Argentina
7
Global
6
Malawi
5
Latin America and the Carribbean
4
Kenya
3
Namibia
3
Africa
3
Brazil
2
Botswana
2
Myanmar / Burma
2
South–East Asia Region
2
Guinea
1
Nigeria
1
Congo, Democratic Republic of
1
Ethiopia
1
Uganda
1
Zimbabwe
1
Philippines
1
Somalia
1
Nepal
1
Zambia
1
Thailand
1
Mozambique
1
Central African Republic
1
Peru
1
Ukraine
1
Colombia
1
Bolivia
1
Lesotho
1
Chile
1
Western Pacific Region
1
Western and Central Europe
1
Venezuela
1
North America
1
Authors & Publishers
Publication Years
Category
Countries
39
Clinical Guidelines
25
Public Health
2
Women & Child Health
2
Pharmacy & Technologies
2
Key Resources
1
Toolboxes
HIV
109
TB
11
Pharmacy
6
COVID-19
3
Conflict
2
Refugee
2
AMR
2
NTDs
2
Mental Health
1
A medida que el tratamiento antirretrovírico con dolutegravir se extiende a más personas que viven con el VIH en el
mundo, adquiere más importancia estimar la frecuencia con que surge la farmacorresistencia adquirida a este
antirretrovírico en
...
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results fr
...
Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on
dolutegravir-based antiretroviral therapy (November 2020– September 2021). Of 64
...
HIV i-Base
July 2018
This technical report summarizes the discussions on the status of programmatic transition to tenofovir, lamivudine and dolutegravir (TLD) in low– and middle- income countries, addressing the best practices and major challenges faced by HIV program
...
Avec l’essor des traitements antirétroviraux (TAR) à base de dolutégravir (DTG) pour soigner les personnes vivant avec
le VIH dans le monde, il est important d’estimer la vitesse à laquelle la résistance acquise au DTG apparaît dans les
...
htb supplement: 2018 Vol 19:(1)
New drugs in development
July 2018
www.i-Base.info
Review
www.co-hivandaids.com
Volume 12 Number 4 July 2017
Technical Update
HIV Treatment
July 2017
July 2019
Policy brief
HIV Treatment
Downloaded from https://aidsinfo.nih.gov/guidelines on 10/19/2019
Developed by the HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—A Working Group of the Office
of AIDS Research Advisory Council (OARAC)
Médecins sans Frontières access campaign
Issue Brief
Accessed: 28.11.2019
Em meados de 2021, os programas nacionais de SIDA começaram a fazer a transição do tratamento para crianças que vivem com VIH dolutegravir (DTG) 10 mg sulcado, comprimidos dispersíveis, também conhecido como DTG pediátrico (pDTG). A rápida i
...
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research toward a cure, and immune-based and gene therapies in development
For the global community to be able to achieve ambitious targets relating to the prevention and treatment of HIV, viral hepatitis and sexually transmitted infections (STIs), multiple types of medicines must be widely accessible to all affected populations in all countries.
The purpose of this rep
...
WHO’s antiretroviral treatment (ART) clinic-based acquired drug resistance survey method yields robust estimates of HIV viral suppression and acquired HIV drug resistance in adults, children and adolescents taking both dolutegravir and non-
...
The report provides a brief introduction to patents and licences and their effect on the market for antiretroviral (ARV) medicines. It gives an overview of the patent landscape with respect to a select number of ARV medicines in developing countries as of April 2014. The focus is primarily on those
...
